Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neutrophil-guided dose escalation of anthracycline/cyclophosphamide chemotherapy in breast cancer
NL-OMON34109Active, not recruiting
- Sponsor
- Ikazia Ziekenhuis
- Start
- Nov 2010
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cyclophosphamide, doxorubicin, epirubicin and fluorouracil in breast cancer, sponsored by Ikazia Ziekenhuis. Primary endpoint: Feasibility of neutrophil-guided dose escalation. Started Nov 2010; status: active, not recruiting.
02
Drugs
cyclophosphamidedoxorubicinepirubicinfluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON34109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34109.